Drug intelligence / Profile preview

palbociclib + pembrolizumab

Development stage: Unknown
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of palbociclib, a CDK4/6 inhibitor, and pembrolizumab, a PD-1 blocking antibody. This combination works by preventing cancer cell division through CDK4/6 inhibition while simultaneously enhancing immune system detection and attack of cancer cells through PD-1 blockade. Clinical trials have shown promising results in hormone receptor-positive (HR+), HER2-negative metastatic breast cancer, particularly when combined with endocrine therapy such as letrozole.

Targets

PDCD1 (Programmed cell death protein 1 receptor)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)

Beyond the preview

Go deeper on palbociclib + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on palbociclib + pembrolizumab.

Explore the full profile